Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells a wide range of medicines and vaccines. Its revenue primarily comes from therapeutic areas such as cardiovascular health, oncology, immunology, and infectious diseases, with notable products including Comirnaty (COVID-19 vaccine), Eliquis (anticoagulant), and Ibrance (breast cancer treatment). The company also engages in contract manufacturing. Revenue shares are approximately 30% from vaccines, 25% from oncology, 20% from cardiovascular and metabolic health, and the remaining 25% from other therapeutic areas. Factors supporting its endurance include a strong pipeline of new drugs and vaccines, while patent expirations and competition from generics could limit its long-term profitability.
—
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells a wide range of medicines and vaccines. Its revenue primarily comes from therapeutic areas such as cardiovascular health, oncology, immunology, and infectious diseases, with notable products including Comirnaty (COVID-19 vaccine), Eliquis (anticoagulant), and Ibrance (breast cancer treatment). The company also engages in contract manufacturing. Revenue shares are approximately 30% from vaccines, 25% from oncology, 20% from cardiovascular and metabolic health, and the remaining 25% from other therapeutic areas. Factors supporting its endurance include a strong pipeline of new drugs and vaccines, while patent expirations and competition from generics could limit its long-term profitability.
—
Daily adjusted close
Pfizer Inc. is a global biopharmaceutical company that discovers, develops, manufactures, markets, distributes, and sells a wide range of medicines and vaccines. Its revenue primarily comes from therapeutic areas such as cardiovascular health, oncology, immunology, and infectious diseases, with notable products including Comirnaty (COVID-19 vaccine), Eliquis (anticoagulant), and Ibrance (breast cancer treatment). The company also engages in contract manufacturing. Revenue shares are approximately 30% from vaccines, 25% from oncology, 20% from cardiovascular and metabolic health, and the remaining 25% from other therapeutic areas. Factors supporting its endurance include a strong pipeline of new drugs and vaccines, while patent expirations and competition from generics could limit its long-term profitability.